Los Angeles Capital Management LLC Sells 25,297 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Los Angeles Capital Management LLC reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 47.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 27,567 shares of the medical equipment provider's stock after selling 25,297 shares during the period. Los Angeles Capital Management LLC's holdings in Lantheus were worth $3,025,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Farallon Capital Management LLC increased its position in shares of Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock valued at $92,316,000 after buying an additional 1,269,900 shares during the period. Swedbank AB purchased a new position in shares of Lantheus during the 1st quarter valued at $26,346,000. Westfield Capital Management Co. LP increased its holdings in shares of Lantheus by 25.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock worth $121,867,000 after purchasing an additional 394,837 shares during the period. Vanguard Group Inc. boosted its stake in Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after buying an additional 389,828 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in Lantheus during the second quarter worth about $26,794,000. Institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on LNTH. Truist Financial reaffirmed a "buy" rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities lowered their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. B. Riley raised their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. Finally, StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Trading Down 6.3 %

LNTH stock traded down $5.39 during midday trading on Wednesday, reaching $79.76. 1,844,913 shares of the company's stock traded hands, compared to its average volume of 1,006,788. The stock's 50-day moving average is $105.95 and its 200 day moving average is $96.28. The stock has a market cap of $5.55 billion, a P/E ratio of 13.27 and a beta of 0.51. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.